Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933730 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL1311637 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL7156151 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL9075213 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3489558 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL28992556 | 0.94 | ALDH1A1 (0.37) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL7153508 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3513773 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL3344516 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB | |
| SCHEMBL28900822 | 0.85 | ALDH1A1 (0.34) | ALDH1A1PDE4AKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087718-A1 | A MULTIVALENT SHIGELLA VACCINE AND METHODS OF MAKING AND USING THEREOF | INSTITUT PASTEUR (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2024-01-25 | — | — | US | disclosed |
| US-20230346902-A1 | Shigella-Tetravalent (Shigella4V) Bioconjugate | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-02 | — | — | US | disclosed |
| EP-4247828-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | Institut Pasteur (FR) | 2023-09-27 | — | — | EP | disclosed |
| EP-4168040-A1 | SHIGELLA-TETRAVALENT (SHIGELLA4V) BIOCONJUGATE | GlaxoSmithKline Biologicals S.A. (BE) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022106703-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021255684-A1 | SHIGELLA-TETRAVALENT (SHIGELLA4V) BIOCONJUGATE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2014013495-A1 | MEMBRANE-TARGETING AMINOGLYCOSIDE-BASED CATIONIC AMPHIPHILES AND THERAPEUTIC USES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346902-A1 | Shigella-Tetravalent (Shigella4V) Bioconjugate | SPIN4, PA2G4, VSIR | ALDH1A1 4249/4885PDE4A 2771/4885KDM4E 2787/4885 |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | SI, DAD1, FUT5 | ALDH1A1 3593/4885PDE4A 4085/4885KDM4E 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.